More information about how BAT may work

We know that “cycling” prostate cancer patients on and off high doses on testosterone while they are on androgen deprivation therapy (ADT) appears to have significant therapeutic benefit in at least some patients (see, for example, here). … READ MORE …

BAT + enzalutamide: data from the RESTORE study

Just over a year ago we wrote up a commentary on this web site entitled, “Can bipolar cycling of testosterone really cure prostate cancer?” It dealt with what is known as “bipolar androgen therapy” or BAT and referred to a Phase II clinical trial known as the RESTORE study. … READ MORE …

Conference call/webinar on bipolar androgen therapy (BAT)

For those who are interested, the Answer Cancer Foundation has let us know that they will be holding an educational conference call/webinar at 8:00 pm Eastern (5:00 pm Pacific) today on the subject of bipolar androgen therapy in the treatment of advanced prostate cancer. … READ MORE …

Can bipolar cycling of testosterone really cure prostate cancer?

Some readers will already have seen headlines like this one from The Vancouver Sun and/or this one from Fox News (which originally seems to have come from The Sun in the UK). … READ MORE …

Androgen deprivation followed by androgen supplementation may increase efficacy of radiotherapy

We have seen the ability of androgen deprivation to increase the efficacy of high dose IMRT in controlling prostate cancer (see this commentary). A new study from Johns Hopkins turns conventional logic on its head … READ MORE …

What is “bipolar” androgen deprivation therapy?

A report just published in Science Translational Medicine describes a new mode of treatment for men with metastatic, castration-resistant prostate cancer (mCRPC) which the authors have called “bipolar” androgen deprivation therapy (BAT). … READ MORE …

What’s “bipolar” androgen therapy? How does it work?

Traditional forms of hormone therapy for prostate cancer are based on the idea that you reduce testosterone levels as low as you can so as to stop the ability of testosterone and its metabolites (e.g., dihydrotestosterone) to stimulate growth of prostatic tissues — including prostate cancer cells. … READ MORE …